Perfluorooctanoate and neuropsychological outcomes in children

Epidemiology

Volumn 24, Issue 4, 2013, Pages 590-599

  Stein, Cheryl R ^a   Savitz, David A ^b   Bellinger, David C ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRINKING WATER; PERFLUOROOCTANOIC ACID;

ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; BLOOD LEVEL; BODY MASS; CHILD; CHILD BEHAVIOR; CHILD DEVELOPMENT; COGNITION; ENVIRONMENTAL EXPOSURE; FEMALE; FUNCTIONAL STATUS; HUMAN; INTELLIGENCE QUOTIENT; LANGUAGE ABILITY; LEARNING; MALE; MATHEMATICS; MEMORY; MENTAL DEVELOPMENT; MENTAL DISEASE; MENTAL PERFORMANCE; NEUROLOGIC DISEASE; NEUROPSYCHOLOGICAL TEST; PRESCHOOL CHILD; PRIORITY JOURNAL; READING; SCHOOL CHILD; WATER CONTAMINATION;

CAPRYLATES; CHILD; CHILD DEVELOPMENT; DRINKING WATER; ENVIRONMENTAL EXPOSURE; FEMALE; FLUOROCARBONS; FOLLOW-UP STUDIES; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84879885827     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0b013e3182944432     Document Type: Article

References (45)

1. Stahl T, Mattern D, Brunn H. Toxicology of perfluorinated compounds. Environ Sci Europe. 2011;23.http://www.enveurope.com/content/23/1/38. Published 6 December 2011. Accessed 9 May 2013.
2. U.S. Environmental Protection Agency. Perfluorooctanoic Acid (PFOA). Available at: http://www.epa.gov/oppt/pfoa/index.html. Accessed 21 January 2009.
3. U.S. Environmental Protection Agency. Perfluorooctanoic Acid (PFOA) and Fluorinated Telomers. Vol. 2009. Washington, DC: U.S. Environmental Protection Agency; 2009.
4. D'eon JC, Mabury SA. Is indirect exposure a significant contributor to the burden of perfluorinated acids observed in humans? Environ Sci Technol. 2011;45: 7974-7984.
5. United Nations Environment Programme. The new POPs under the Stockholm Convention. Available at: http://chm.pops.int/Implementation/ NewPOPs/TheNewPOPs/tabid/672/Default.aspx Accessed 25 May 2012.
6. White SS, Fenton SE, Hines EP. Endocrine disrupting properties of perfluorooctanoic acid. J Steroid Biochem Mol Biol. 2011;127: 16-26.
7. Houde M, Martin JW, Letcher RJ, Solomon KR, Muir DC. Biological monitoring of polyfluoroalkyl substances: A review. Environ Sci Technol. 2006;40: 3463-3473.
8. Kato K, Wong LY, Jia LT, Kuklenyik Z, Calafat AM. Trends in exposure to polyfluoroalkyl chemicals in the U.S. population: 1999-2008. Environ Sci Technol. 2011;45: 8037-8045.
9. Jensen MS, Nørgaard-Pedersen B, Toft G, et al. Phthalates and perfluorooctanesulfonic acid in human amniotic fluid: temporal trends and timing of amniocentesis in pregnancy. Environ Health Perspect. 2012;120: 897-903.
10. Stein CR, Wolff MS, Calafat AM, Kato K, Engel SM. Comparison of polyfluoroalkyl compound concentrations in maternal serum and amniotic fluid: a pilot study. Reprod Toxicol. 2012;34: 312-316.
11. Monroy R, Morrison K, Teo K, et al. Serum levels of perfluoroalkyl compounds in human maternal and umbilical cord blood samples. Environ Res. 2008;108: 56-62.
12. I noue K, Okada F, Ito R, et al. Perfluorooctane sulfonate (PFOS) and related perfluorinated compounds in human maternal and cord blood samples: assessment of PFOS exposure in a susceptible population during pregnancy. Environ Health Perspect. 2004;112: 1204-1207.
13. Midasch O, Drexler H, Hart N, Beckmann MW, Angerer J. Transplacental exposure of neonates to perfluorooctanesulfonate and perfluorooctanoate: a pilot study. Int Arch Occup Environ Health. 2007;80: 643-648.
14. T ao L, Kannan K, Wong CM, Arcaro KF, Butenhoff JL. Perfluorinated compounds in human milk from Massachusetts, U.S.A. Environ Sci Technol. 2008;42: 3096-3101.
15. T ao L, Ma J, Kunisue T, Libelo EL, Tanabe S, Kannan K. Perfluorinated compounds in human breast milk from several Asian countries, and in infant formula and dairy milk from the United States. Environ Sci Technol. 2008;42: 8597-8602.
16. Völkel W, Genzel-Boroviczény O, Demmelmair H, et al. Perfluorooctane sulphonate (PFOS) and perfluorooctanoic acid (PFOA) in human breast milk: results of a pilot study. Int J Hyg Environ Health. 2008;211: 440-446.
17. Kuklenyik Z, Reich JA, Tully JS, Needham LL, Calafat AM. Automated solid-phase extraction and measurement of perfluorinated organic acids and amides in human serum and milk. Environ Sci Technol. 2004;38: 3698-3704.
18. So MK, Yamashita N, Taniyasu S, et al. Health risks in infants associated with exposure to perfluorinated compounds in human breast milk from Zhoushan, China. Environ Sci Technol. 2006;40: 2924-2929.
19. Bartell SM, Calafat AM, Lyu C, Kato K, Ryan PB, Steenland K. Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia. Environ Health Perspect. 2010;118: 222-228.
20. Olsen GW, Burris JM, Ehresman DJ, et al. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect. 2007;115: 1298-1305.
21. U.S. Environmental Protection Agency. 2010/2015 PFOA Stewardship Program. Available at: http://www.epa.gov/oppt/pfoa/pubs/stewardship/ index.html. Accessed 29 March 2012.
22. L au C, Anitole K, Hodes C, Lai D, Pfahles-Hutchens A, Seed J. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci. 2007;99: 366-394.
23. L au C, Butenhoff JL, Rogers JM. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol Appl Pharmacol. 2004;198: 231-241.
24. Olsen GW, Butenhoff JL, Zobel LR. Perfluoroalkyl chemicals and human fetal development: an epidemiologic review with clinical and toxicological perspectives. Reprod Toxicol. 2009;27: 212-230.
25. Fei C, McLaughlin JK, Lipworth L, Olsen J. Prenatal exposure to perfluorooctanoate (PFOA) and perfluorooctanesulfonate (PFOS) and maternally reported developmental milestones in infancy. Environ Health Perspect. 2008;116: 1391-1395.
26. Fei C, Olsen J. Prenatal exposure to perfluorinated chemicals and behavioral or coordination problems at age 7 years. Environ Health Perspect. 2011;119: 573-578.
27. Hoffman K, Webster TF, Weisskopf MG, Weinberg J, Vieira VM. Exposure to polyfluoroalkyl chemicals and attention deficit/hyperactivity disorder in U.S. children 12-15 years of age. Environ Health Perspect. 2010;118: 1762-1767.
28. Stein CR, Savitz DA. Serum perfluorinated compound concentration and attention deficit/hyperactivity disorder in children 5-18 years of age. Environ Health Perspect. 2011;119: 1466-1471.
29. G ump BB, Wu Q, Dumas AK, Kannan K. Perfluorochemical (PFC) exposure in children: associations with impaired response inhibition. Environ Sci Technol. 2011;45: 8151-8159.
30. Frisbee SJ, Brooks AP Jr, Maher A, et al. The C8 health project: design, methods, and participants. Environ Health Perspect. 2009;117: 1873-1882.
31. Flaherty JM, Connolly PD, Decker ER, et al. Quantitative determination of perfluorooctanoic acid in serum and plasma by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;819: 329-338.
32. Shin HM, Vieira VM, Ryan PB, et al. Environmental fate and transport modeling for perfluorooctanoic Acid emitted from the washington works facility in west virginia. Environ Sci Technol. 2011;45: 1435-1442.
33. Shin HM, Vieira VM, Ryan PB, Steenland K, Bartell SM. Retrospective exposure estimation and predicted versus observed serum perfluorooctanoic acid concentrations for participants in the C8 Health Project. Environ Health Perspect. 2011;119: 1760-1765.
34. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med. 2010;29: 1037-1057.
35. T he Psychological Corporation. Wechsler Abbreviated Scale of Intelligence. San Antonio, TX: Harcourt Brace and Company; 1999.
36. The Psychological Corporation. Wechsler Individual Achievement Test. 2nd ed. San Antonio, TX: Harcourt Assessment Company; 2002.
37. Korkman M, Kirk U, Kemp S. NEPSY II. 2nd ed. San Antonio, TX: NCS Pearson, Inc.; 2007.
38. Conners CK. Conners' CPT II for Windows. In: Staff M, ed. North Tonawanda, NY: Multi-Health Systems, Inc.; 2004.
39. National Longitudinal Survey Program. National Longitudinal Survey Program. Available at: http://www.bls.gov/nls/nlsy97.htm. Accessed 25 May 2012.
40. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1998.
41. Power MC, Webster TF, Baccarelli AA, Weisskopf MG. Crosssectional association between polyfluoroalkyl chemicals and cognitive limitation in the National Health and Nutrition Examination Survey. Neuroepidemiology. 2013;40: 125-132.
42. Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator- activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol Sci. 2006;92: 476-489.
43. Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci. 2008;13: 1813-1826.
44. Kaundal RK, Sharma SS. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. Drug News Perspect. 2010;23: 241-256.
45. Bellinger DC. The protean toxicities of lead: new chapters in a familiar story. Int J Environ Res Public Health. 2011;8: 2593-2628.